［1］Younossi ZM,Koenig AB,Abdelatif D,et al.Global epidemiology of nonalcoholic fatty liver disease:Metaanalytic assessment of prevalence, incidence and outcomes\[J\].Hepatology,2016, 64(1): 73-84.［2］PortilloSanchez P,Bril F,Maximos M, et al. High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels\[J\]. J Clin Endocrinol Metab,2015,100(6): 2231-2238.［3］Williamson RM,Price JF,Glancy S,et al. Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes:The Edinburgh type 2 diabetes study\[J\].Diabetes Care,2011,34(5): 1139-1144.［4］Xiong J,Wang J, Huang J, et al. Nonalcoholic steatohepatitisrelated liver cirrhosis is increasing in China: a tenyear retrospective study\[J\]. Clinics(Sao Paulo),2015,70(6): 563-568.［5］Oda K,Uto H,Mawatari S,et al. Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: A review of human studies\[J\]. Clin J Gastroenterol,2015, 8(4): 1-9.［6］Armstrong MJ, Houlihan DD, Rowe IA, et al. Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes:individual patient data metaanalysis of the LEAD program\[J\]. Aliment Pharmacol Ther,2013,37(2):234-242.［7］杨帆,李钶,蒋晓岚,等.利拉鲁肽对肥胖2型糖尿病合并非酒精性脂肪肝患者的肝脏脂肪沉积的影响研究\[J\].重庆医学,2016,45(325):3493-3495.［8］Xia MF, Yan HM, He WY， et al. Standardized ultrasound hepatic/renal ratio and hepatic attenuation rate to quantify liver fat content:An improvement method\[J\].Obesity(Silver Spring),2012,20(9): 444-452.［9］Xia MF, Ling Y, Bian H,et al.I148M variant of PNPLA3 increases the susceptibility to nonalcoholic fatty liver disease caused by obesity and metabolic disorders\[J\]. Aliment Pharmacol Ther,2016,43(4): 631-642.［10］Li H, Wu G, Fang Q, et al. Fibroblast growth factor 21 increases insulin sensitivity through specific expansion of subcutaneous fat\[J\]. Nat Commun,2018,9(1):272.［11］Li H, Fang Q, Gao F,et al. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride\[J\]. J Hepatol, 2010,53(5):934-940.［12］Gong Q, Hu Z, Zhang F, et al. Fibroblast growth factor 21 improves hepatic insulin sensitivity by inhibiting mammalian target of rapamycin complex 1\[J\]. Hepatology,2016,64(2):425-438.［13］Li H,Dong K,Fang Q,et al.High serum level of fibroblast growth factor 21 is an independent predictor of nonalcoholic fatty liver disease:a 3year prospective study in China\[J\].J Hepatol, 2013,58(3):557-563.［14］Li Y, Wong K, Giles A. Hepatic SIRT1 attenuates hepatic steatosis and controls energy balance in mice by inducing fibroblast growth factor 21\[J\]. Gastroenterology,2014,146(2):539-549.［15］Li Y,Wong K,Walsh K,et al. Retinoic acid receptor β stimulates hepatic induction of fibroblast growth factor 21 to promote fatty acid oxidation and control wholebody energy homeostasis in mice\[J\]. J Biol Chem,2013,288(15):10490-10504.［16］王翠华,岳妍.瘦素、脂联素与非酒精性脂肪性肝病关系的研究进展\[J\].临床肝胆病杂志,2015,31(8):1351-1354.［17］Hsieh CJ,Wang PW,Hu TH.Association of adiponectin gene polymorphism with nonalcoholic fatty liver disease in Taiwanese patients with type 2 diabetes\[J\]. PLoS One,2015,10(6):e0127521.
2018, Vol. 28 
